? Breast Cancer Program The Breast Cancer Program (BCP) of the Abramson Cancer Center (ACC) is a multidisciplinary team of highly productive investigators focused on a common goal: to reduce the burden and mortality of breast cancer by elucidating biological mechanisms underlying the disease and translating this knowledge to improved detection, prevention and treatment. BCP members are highly collaborative, working on interconnected scientific aims that span the continuum from basic science to clinical research.
Specific Aims are: 1) Elucidate the biologic, genetic and molecular mechanisms of breast cancer development and progression; 2) Advance understanding of genetic susceptibility to optimize screening and prevention for those at risk; 3) Develop innovative imaging approaches to improve breast cancer screening, detection and biomarkers to guide treatment and assess therapeutic response, and 4) Translate laboratory discoveries to clinical trials of novel therapeutics, incorporating biomarkers of response and outcome. Members made fundamental discoveries to identify breast cancer drivers, mechanisms of tumor dormancy and genome integrity, interferon response, and the relationship between radiation and immunogenicity. These findings were translated into new targeted therapeutics, novel combinations, genomic and predictive assays, and cutting-edge imaging methods and probes. Program members design and implement innovative clinical trials, leading clinical/translational teams within the ACC, nationally and internationally. In the current funding period, there were 1,386 accruals onto interventional trials and 14,079 accruals onto non-interventional trials. The complementary skills of Program co-Leaders (PLs) Angela DeMichele, MD, MSCE (clinical trials/biomarkers) and Roger Greenberg, MD, PhD (basic science/genetics) facilitate intra- and inter- Programmatic collaborations. With clinical translation of basic science as a major focus, the PLs expanded clinical research units for breast cancer and genetics, grew and curated large biospecimen banks, and recruited exceptional senior and junior faculty. These developments have fostered new ideas and collaborations supported by ACC pilot funds. The PLs also initiated two new basic science centers, the Center for Genome Integrity and the Mark Foundation Center. The 25 members of BCP come from seven University Departments and two Schools, reflecting diverse expertise. BCP members hold $10.4M in cancer-related grant funding (annual direct costs), of which $6.6M is peer-reviewed and $4.3M is NCI-funded. Members hold 26 R01s or equivalent (of which six are multi-PI awards), an NCI R33 Moonshot Grant, and a DOD Breast Cancer Center of Excellence. Over the current funding cycle, BCP members published 403 cancer-related papers, of which 22% were intra-Programmatic collaborations, 37% were inter- Programmatic collaborations, and 72% were multi-institutional in nature. Supported by senior clinical leaders within the National Accreditation Program for Breast Centers-accredited Rowan Breast Center, BCP generates high-impact, practice-changing research, moving the needle on breast cancer treatment and outcomes.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016520-45
Application #
10088744
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-01-15
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Huang, Mo; Wang, Jingshu; Torre, Eduardo et al. (2018) SAVER: gene expression recovery for single-cell RNA sequencing. Nat Methods 15:539-542
Yam, Clinton; Xu, Xiaowei; Davies, Michael A et al. (2018) A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors. Clin Cancer Res 24:22-32
Onorati, Angelique V; Dyczynski, Matheus; Ojha, Rani et al. (2018) Targeting autophagy in cancer. Cancer 124:3307-3318
Rebecca, Vito W; Nicastri, Michael C; Fennelly, Colin et al. (2018) PPT1 promotes tumor growth and is the molecular target of chloroquine derivatives in cancer. Cancer Discov :
Garfall, Alfred L; Stadtmauer, Edward A; Hwang, Wei-Ting et al. (2018) Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. JCI Insight 3:
Jang, Jeong Hoon; Manatunga, Amita K; Taylor, Andrew T et al. (2018) Overall indices for assessing agreement among multiple raters. Stat Med 37:4200-4215
Scheel, John R; Kim, Eunhee; Partridge, Savannah C et al. (2018) MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol 210:1376-1385
Romero, Sally A D; Brown, Justin C; Bauml, Joshua M et al. (2018) Barriers to physical activity: a study of academic and community cancer survivors with pain. J Cancer Surviv 12:744-752
Hinderer, Christian; Katz, Nathan; Buza, Elizabeth L et al. (2018) Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human SMN. Hum Gene Ther 29:285-298
Li, Jinyang; Byrne, Katelyn T; Yan, Fangxue et al. (2018) Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy. Immunity 49:178-193.e7

Showing the most recent 10 out of 1047 publications